11 October 2022: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Table 2 Engraftment, infection, acute and chronic GVHD, and other complications after MSD-PBSCT.
| Outcomes | ATG group | Non-ATG group | p value |
|---|---|---|---|
| Early death, No. (%) | 0 | 0 | |
| Neutrophil engraftment, d, median (range) | 12 (8–18) | 10 (9–32) | 0.060 |
| Platelet engraftment, d, median (range) | 12 (7–29) | 13 (9–75) | 0.084 |
| Cytomegalovirus reactivation at day +180, No. (%) | 8 (20.0) | 8 (17.8) | 0.794 |
| Epstein-Barr virus reactivation at day +180, No. (%) | 15 (37.5) | 2 (4.4) | |
| PTLD, No. (%) | 0 | 0 | |
| Grades of aGVHD, No. (%) | 0.784 | ||
| 0 | 22 (55.0) | 28 (62.2) | |
| 1 | 3 (7.5) | 4 (8.9) | |
| 2 | 13 (32.5) | 11 (24.4) | |
| 3 | 1 (2.5) | 2 (4.4) | |
| 4 | 1 (2.5) | 0 (0.0) | |
| 2–4 | 15 (37.5) | 13 (28.9) | |
| 3–4 | 2 (5.0) | 2 (4.4) | |
| Severity of cGVHD according to revised Seattle criteria, No. (%)* | |||
| No cGVHD | 33 (82.5) | 17 (38.6) | |
| Limited | 5 (12.5) | 17 (38.6) | |
| Extensive | 2 (5.0) | 10 (22.8) | |
| Severity of cGVHD according to NIH criteria, No. (%)* | 0.001 | ||
| No cGVHD | 33 (82.5) | 17 (38.6) | |
| Mild | 3 (7.5) | 13 (29.5) | |
| Moderate | 3 (7.5) | 9 (20.5) | |
| Severe | 1 (2.5) | 5 (11.4) | |
| ATG – anti-thymocyte globulin; PTLD – post-transplantation lympho-proliferative disorder; aGVHD – acute graft-versus-host disease; cGVHD – chronic graft-versus-host disease; no. – number of patients. * 1 patient died within 100 days. | |||